Hemophilia A With Inhibitor Clinical Trial
Official title:
Basic Study on Novel Therapeutic Strategy With Bypassing Agent Therapy in Hemophilia A Patients With Inhibitors
Using whole blood samples and plasma samples obtained from some hemophilia A patients with inhibitors, the investigators will perform the coagulation assessment in the co-presence of aPCC and factor VIII by comprehensive coagulation assays and flow chamber analysis under blood flow conditions.
Comprehensive coagulation assays using recently popular rotational thromboelastometry (ROTEM), factor Xa/thrombin/plasmin generation test, and coagulation wave analysis and recently developed flow chamber system under blood flow conditions (T-TAS®) will be used. A bypassing agent, aPCC (Feiba®) and recombinant factor VIII (Advate®) will be added ex vivo to whole blood and plasma samples from patients with hemophilia A with inhibitors to compare with the coagulation effects of aPCC in the presence of factor VIII and those of aPCC in its absence under the conditions close to the physiological condition. Furthermore, the difference in the coagulation effects by the difference in inhibitor epitopes will be examined. ;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06320626 -
Pharmacokinetic-guided Dosing of Emicizumab
|
Phase 4 | |
| Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
| Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
| Active, not recruiting |
NCT03619863 -
ATHN 7: Hemophilia Natural History Study
|
||
| Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
| Completed |
NCT03951103 -
rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
|
||
| Recruiting |
NCT05888870 -
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
|
Phase 4 | |
| Terminated |
NCT04303572 -
The Hemophilia Inhibitor Eradication Trial
|
Phase 3 | |
| Terminated |
NCT04489537 -
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
|
Phase 3 | |
| Terminated |
NCT04548791 -
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT06357572 -
Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
|
||
| Recruiting |
NCT04647227 -
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
|
Phase 4 | |
| Completed |
NCT03372993 -
Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
|
||
| Terminated |
NCT03204539 -
INdividualized ITI Based on Fviii(ATE) Protection by VWF
|
Phase 4 | |
| Active, not recruiting |
NCT04205175 -
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
|
Phase 4 | |
| Recruiting |
NCT06312475 -
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
|
Phase 3 | |
| Recruiting |
NCT03598725 -
Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China
|
Phase 4 | |
| Completed |
NCT04723693 -
An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
|
||
| Completed |
NCT04789954 -
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
|
Early Phase 1 | |
| Recruiting |
NCT04592692 -
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
|
Phase 2 |